RxDoctor Payments Data

Sarwar Husain, MD

Internal Medicine · Chicago, ILNPI 1215005822

Payments from drug & device makers

$306in general payments, 2019–2025

Across 17 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$95
  • Ascensia Diabetes Care US Inc.$57
  • Omeza LLC$53
  • Exact Sciences$46
  • Pfizer$20
  • AstraZeneca$17
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk4$95
Ascensia Diabetes Care US Inc.1$57
Omeza LLC7$53
Exact Sciences2$46
Pfizer1$20
AstraZeneca1$17
Dexcom, Inc.1$17

How this compares

$306 in reported general payments places this provider in the 60th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$227,829
Medicare patients
286
Services billed
2,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$103,971
JardianceEmpagliflozin14$21,583
XareltoRivaroxaban13$21,024
Breo ElliptaFluticasone/Vilanterol19$16,991
AbrysvoRsv Vacc, Pref A And Pref B/Pf44$14,003
JanuviaSitagliptin Phosphate12$10,442
LinzessLinaclotide14$9,095
Atorvastatin Calcium621$6,206
ShingrixVaricella-Zoster Ge/As01b/Pf26$5,699
Levothyroxine Sodium324$4,064
Arnuity ElliptaFluticasone Furoate13$3,177
Metoprolol Succinate201$3,032
Losartan Potassium256$2,991
Amlodipine Besylate285$2,966
Gabapentin119$2,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$20$117,974135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →